It's been almost a yearlong contest, but a deal for patchmaker LTS Lohmann appears to be nearing the finish line. The private equity firm Nordic Capital is likely to beat out competitor Wendel for the deal, Bloomberg says, at a price of about $1.7 billion.
All things being relative, 2013 was a pretty good year for M&A in pharma. There were 169 deals valued at $76 billion last year, according to the information ninjas who dice the numbers at...
Surgical device maker Conmed ($CNMD) is said to be putting itself up for sale, ostensibly to avoid trouble from activist shareholders at its annual meeting later this year.
European biotechs BioAlliance Pharma and Topotarget have signed up to join forces, plotting to merge under the former's name and combine their pipelines of late-stage oncology drugs.
Certara, an informatics-focused pharma contractor, has bought up specialty CRO Synchrogenix, absorbing a company devoted to regulatory writing with hopes of expanding its market share.
GE Healthcare has been no stranger to dealmaking over the past year, and the company's CEO said it has no plans to let up.
ERBA Diagnostics has something to crow about for 2013. Year-over-year, the Florida in vitro diagnostics outfit swung from a net loss to a small profit, aided, in part, by a surge in new revenue stemming from a 2012 acquisition. The company said it is eyeing more M&A deals in 2014.
Just over a month into its search for "strategic options," ThromboGenics has rounded up a bevy of high-dollar offers that could value the company at as much as $1.3 billion, Bloomberg reports, courted by drugmakers who see promise in its underperforming eye drug.
NeoStem says it will acquire California Stem Cell and a Phase III-ready cancer immunotherapy.
Irish medical device giant Covidien has purchased Florida-based New Wave Surgical for more than $100 million.